Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05248230 · ClinicalTrials.gov registry record · Phase 2
4D-710 in Adult Patients With Cystic Fibrosis
A Phase 2 study of Cystic Fibrosis Lung, sponsored by 4D Molecular Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT05248230 is a Phase 2 study of Cystic Fibrosis Lung that is actively recruiting participants, run by 4D Molecular Therapeutics. The registered enrollment target is 30 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05248230, a Phase 2 study of Cystic Fibrosis Lung, is actively recruiting participants, sponsored by 4D Molecular Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
Conditions Studied
Interventions
- BIOLOGICAL 4D-710
Study Locations (20)
Florida
- University of Florida - Gainesville
- University of Miami Hospital - Miami
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
Ohio
- Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center - Cleveland
- Nationwide Children's Hospital - Columbus
Pennsylvania
- Penn State Health - Hershey
- The Hospital of the University of Pennsylvania - Philadelphia
Alabama
- University of Alabama Child Health Research Unit - Birmingham
Arizona
- The University of Arizona - Tucson
California
- University of California San Francisco - San Francisco
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2031-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05248230
The ClinicalTrials.gov registry entry for NCT05248230 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 4D Molecular Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis Lung appearing as the primary indexed condition, and to 1 intervention - of which 4D-710 is the first listed.
NCT05248230 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05248230 about?
NCT05248230 is a clinical study titled "4D-710 in Adult Patients With Cystic Fibrosis". This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
What is the current status of trial NCT05248230?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-03-29. Estimated completion is 2031-06.
What conditions does trial NCT05248230 study?
This clinical trial studies the following conditions: Cystic Fibrosis Lung.
What interventions are being tested in trial NCT05248230?
The interventions under investigation include: 4D-710 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05248230?
This trial is sponsored by 4D Molecular Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05248230 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.